Yourgene Health PLC Exercise of Warrants and Options (4070N)
20 Mayo 2020 - 1:00AM
UK Regulatory
TIDMYGEN
RNS Number : 4070N
Yourgene Health PLC
20 May 2020
Yourgene Health plc
("Yourgene" or the "Company")
Exercise of Warrants and Options
Manchester, UK - 20 May 2020: Yourgene (AIM: YGEN), a leading
international molecular diagnostics group, received notification of
the following exercise of options and warrants:-
-- For the exercise of options over 6,437,565 ordinary shares in
the Company at an exercise price of 10 pence per share providing
the Company with proceeds of GBP643,756.50 ("Options Exercise").
The options are being exercised by two former employees prior to
the expiry of the option.
-- For the exercise of warrants over 1,411,427 ordinary shares
in the Company at an exercise price of 11 pence per share providing
the Company with proceeds of GBP155,256.97 ("Warrant Exercise").
The warrant is being exercised by an adviser on the 2014 Admission
to AIM prior to the expiry of the warrants.
Application will be made to the London Stock Exchange to admit
the aggregate 7,848,992 new ordinary shares resulting from the
Options Exercise and Warrant Exercise to trading on AIM. Admission
of the new ordinary shares is expected to occur on or around 26 May
2020. The new ordinary shares will rank pari passu with the
existing ordinary shares.
For the purpose of the Disclosure and Transparency Rules,
following the issue of shares detailed above the enlarged issued
share capital of the Company will comprise 624,331,197 ordinary
shares of 0.1p each. The Company does not hold any ordinary shares
in treasury. The above figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company, under the Disclosure and Transparency
Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
Stifel Nicolaus Europe Limited (Sole Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which
develops and commercialises genetic products and services. The
group works in partnership with global leaders in DNA technology to
advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, primarily for reproductive health.
The Group's products include non-invasive prenatal tests (NIPT) for
Down's Syndrome and other genetic disorders, Cystic Fibrosis
screening tests, invasive rapid aneuploidy tests, male infertility
tests and genetic disease tests. Yourgene's commercial footprint is
already established in the UK, Europe, the Middle East, Africa and
Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene is also extending its genetic
testing offering into oncology.
Yourgene is headquartered in Manchester, UK with offices in
Taipei and Singapore, and is listed on the London Stock Exchange's
AIM market under the ticker "YGEN". For more information, visit
www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEUKVKRRWUVAAR
(END) Dow Jones Newswires
May 20, 2020 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Yourgene Health (LSE:YGEN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024